Phase 3 Liver Disease Clinical Trials
8 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 3
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Chronic Liver Disease
Green Cross Wellbeing226 enrolled1 locationNCT06493799
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled331 locationsNCT06318169
Recruiting
Phase 3
The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Jiangsu HengRui Medicine Co., Ltd.101 enrolled1 locationNCT06507436
Recruiting
Phase 3
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
OverweightMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled1 locationNCT06884293
Recruiting
Phase 3
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Liver DiseasesPortal Hypertension
Thomas Jefferson University660 enrolled3 locationsNCT05470205
Recruiting
Phase 3
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Hepatocellular CarcinomaAdvanced Chronic Liver DiseasePortal Hypertension
Hospital Universitari Vall d'Hebron Research Institute300 enrolled1 locationNCT06434753
Not Yet Recruiting
Phase 3
The effect of ertugliflozin in patients with nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus.
Elevated liver enzymesNon alcoholic acute Steatohepatitis (NASH)Fatty liver diseases+1 more
Abdul Wali Khan University180 enrolled1 locationACTRN12624000032550